ClinicalTrials.gg
CompletedNCT05743634Updated Feb 24, 2023

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

A Phase 1/2 interventional study of YY001 and OnabotulinumtoxinA in Moderate to Severe Glabellar Lines, sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd.. Completed at 6 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Chongqing Claruvis Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Mar 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The study has been designed to test the safety,efficacy,immunogenicity of YY001,and compare to onabotulinumtoxinA (BOTOX®) and placebo, in improving the appearance of moderate to severe glabellar lines.

02

Conditions studied

  • Moderate to Severe Glabellar Lines

Keywords

  • YY001
  • Botulinum Toxin
  • Glabellar Lines
03

In context

Lead sponsor

Chongqing Claruvis Pharmaceutical Co., Ltd. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects from ≥18 to ≤65 years of age when signing an .
  2. At screening and baseline,the subject has moderate to severe GL (grade of 2 or 3 on the 4-point Scale) at maximum frown when assessed by both the Investigator and the subject.
  3. Agree to take part in the clinic trial and sign the informed consent form voluntarily.
  4. Is able to observe the protocol by Investigator's assessment.
  5. Male and female of agree to use a highly effective method for the duration of the study(such as tubal ligation,abstinence,Intrauterine device,hormone,barrier method).For female of childbearing potential,her blood pregnancy test is negative within 7 days prior to study treatment,and urine pregnancy test is negative within 3 days prior to study treatment.Male can't donate the sperm within 3 months after treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to any component of the study products(YY001 or BOTOX®).
  2. Previous use of any cosmetic therapy in the glabella or forehead area,such as hyaluronic acid,phototherapy,hydrating needle,microneedle,chemical peeling,scar removal surgery or skin dermabrasion within 6 months before screening.Previous use of biodegradable filler within 12 months before screening,such as collagen,polylactic acid or calcium hydroxyapatite.Previous use of autologous fat, any permanent products (such as silicone, polyacrylamide,no matter how long the interval is) ,face-lift,or semi-permanent prosthesis.Planned use of any cosmetic therapy in the glabella or forehead area during the study(other than the study products).
  3. Previous use of any botulinum toxin within 6 months prior to screening,or plan to use any botulinum toxin during the study(other than the study products).
  4. Use of any non- anti-inflammatory drug or anticoagulant within 1 week prior to study treatment.
  5. Use of medications that affect neuromuscular transmission within 4 weeks prior to screening, such as muscle relaxant,aminoglycoside antibiotics,anticholinergic drugs,benzodiazepines,etc.
  6. Probably use of prohibited drug during the study,as assessed by the investigator.
  7. Abnormal skin at in the treatment area,scar or physical scars, in the investigator's opinion,may interfere with study evaluations.
  8. Inability to substantially spread glabellar lines apart by surgery or finger smoothing, as determined by the investigator.
  9. Ptosis,excessive facial asymmetry and skin laxity ,at screening and baseline.
  10. History of facial nerve palsy.
  11. Any medical condition that may interfere neuromuscular function including myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, dysphagia,dyspnea,diplopia,angle-closure glaucoma,eyelid or eyebrow ptosis,etc.
  12. Any concomitant disease including,unfit for the study by the investigator.
  13. In acute attack.
  14. Abnormal lab findings,and unfit for the study in the opinion of the investigator.
  15. History of alcohol or drug abuse.
  16. History of epilepsy.
  17. Any severe psychiatric illness ,in the investigator's opinion, could affect the subject's participation in the study.
  18. Female who is pregnant,or breast feeding.
  19. In any other clinical study ,or Participated in any other interventional study within 30 days or 5 half-lives prior to screening.
  20. Contract research organization,study site personnel or close relatives of the study site personnel , employees or close relatives of employees at the sponsor company.
  21. Other conditions, in the Investigator's opinion, unfit for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Single injection with YY001 in glabellar lines

    Biological: YY001

  • Active comparator
    Active-Controlled Group

    Single injection with BOTOX® in glabellar lines

    Biological: OnabotulinumtoxinA

  • Placebo comparator
    Placebo-Controlled Group

    Single injection with placebo in glabellar lines

    Biological: Placebo

Interventions

  • BiologicalYY001

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

  • Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

  • BiologicalPlacebo

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

06

What researchers measure

Primary outcomes

  1. Phase1:The incidence rate of adverse events and severe adverse events within 28 days after injection

    Time frame: Within 28 days

  2. Phase1:The incidence rate of injection site reaction within 28 days after injection

    Time frame: Within 28 days

  3. Phase1:The incidence rate of abnormal lab findings which have clinical significance within 28 days after injection

    Time frame: Within 28 days

  4. Phase2:The response rate will be evaluated at 28 days by investigator at maximum frown

    A response rate is defined as a subject who achieves a score of 0 or 1 in GL severity at maximum frown and at least 2 grades improvement from baseline by investigator's assessment

    Time frame: 28 days

  5. Phase2:The incidence rate of adverse events and severe adverse events within 12 weeks after injection

    Time frame: within 12 weeks

  6. Phase2:The incidence rate of injection site reaction within 12 weeks after injection

    Time frame: within 12 weeks

07

Study locations

6 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • The First affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Nanfang Hospital,Southern Medical University
    Guangzhou, Guangdong, China
  • Shanghai Ninth People's Hospital,Shanghai JiaoTong University school of Medicine
    Shanghai, Shanghai, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Feb 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 24, 2023
StartActual
Mar 22, 2022
Primary completionActual
Feb 13, 2023
CompletionActual
Feb 13, 2023
Last update
Feb 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743634
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Mar 22, 2022
Primary completion
Feb 13, 2023
Completion
Feb 13, 2023
Last update
Feb 24, 2023

Study contacts

Qingfeng Li
principal investigator · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EP4 Receptor Antagonist YY001

Start the discussion